DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Apresoline (Hydralazine Hydrochloride) - Published Studies


Apresoline Related Published Studies

Well-designed clinical trials related to Apresoline (Hydralazine)

Hydralazine for essential hypertension. [2011.11.09]

Comparison of the efficacy of nifedipine and hydralazine in hypertensive crisis in pregnancy. [2011.11]

Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. [2011.01]

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. [2010.10.08]

Hydralazine for essential hypertension. [2010.08.04]

Effects of dihydralazine on renal water and aquaporin-2 excretion in humans. [2009]

Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial). [2007.08.15]

Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. [2007.06]

Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. [2007.04.03]

Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. [2006.09]

Antihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. [2006.08]

A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. [2006.05]

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. [2004.11.11]

Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. [2002.01]

An open trial comparing isradipine with hydralazine and methyl dopa in the treatment of patients with severe pre-eclampsia. [1999.05]

Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome. [1999.02]

Vasodilator therapy of hypertensive acute left ventricular failure: comparison of captopril-prazosin with hydralazine-isosorbide dinitrate. [1998.11.30]

The haemodynamic effects of ketanserin versus dihydralazine in severe early-onset hypertension in pregnancy. [1998.07]

Treatment of hypertension in patients with pre-eclampsia: a prospective parallel-group study comparing dihydralazine with urapidil. [1998.02]

Dihydralazine or ketanserin for severe hypertension in pregnancy? Preliminary results. [1997.12]

The effect of hydralazine on the development of tolerance to continuous nitroglycerin. [1997.02]

Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. [1995.12]

Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. [1995.08]

Ketanserin and hydralazine in hypertension in pregnancy--a randomised double-blind trial. [1995.06]

Topically applied hydralazine: effects on systemic cardiovascular parameters, blood-aqueous barrier, and aqueous humor dynamics in normotensive humans. [1995.06]

Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. [1994.10]

Comparison of outcome of labetalol or hydralazine therapy during hypertension in pregnancy in very low birth weight infants. [1993.11]

Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]

Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. [1993.06]

Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group. [1993.06]

Malignant ventricular arrhythmias in eclampsia: a comparison of labetalol with dihydralazine. [1993.04]

[Management of severe pre-eclampsia/eclampsia. Comparison between nifedipine and hydralazine as antihypertensive agents] [1993.03]

Comparison of captopril, hydralazine and nifedipine as third drug in hypertensive patients. [1993.02]

A randomized comparison between the hemodynamic effects of hydralazine and nitroglycerin alone and in combination at rest and during isometric exercise in patients with chronic mitral regurgitation. [1993.01]

A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy. [1992.09]

Comparative bioavailability of a sustained-release ion-exchange hydralazine product with a potassium (cation) challenge. [1992.06]

Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia. [1992.05]

Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. [1992.03.15]

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. [1991.08.01]

Interactions between hydralazine and oral nutrients in humans. [1991.07]

[Management of severe pre-eclampsia in the puerperium. Comparative study of sublingual nifedipine and hydralazine] [1991.07]

Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol. [1991.05]

Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine. [1991.01]

Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients. [1990.10]

Hydralazine dose-response curve analysis. [1990.08]

Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy. [1990.04]

Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. [1990.03]

Hydralazine does not stimulate prostacyclin biosynthesis in hypertensive patients. [1990.03]

Utilization of hydralazine or alpha-methyldopa for the management of early puerperal hypertension. [1989.10]

Comparative hemodynamic effects of labetalol and hydralazine in the treatment of postoperative hypertension. [1989]

Antihypertensive effect of felodipine or hydralazine when added to beta-blocker therapy. [1988.07]

Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension. [1988]

Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker. [1987.02]

Comparative efficacy and safety of immediate-release and controlled-release hydralazine in black hypertensive patients. [1987]

Well-designed clinical trials possibly related to Apresoline (Hydralazine)

Left ventricular responses to acute changes in late systolic pressure augmentation in older adults. [2013]

Pharmacotherapy review of chronic pediatric hypertension. [2011.10]

Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT). [2011.07]

Treatment of heart failure in African Americans--a call to action. [2011.02]

Treatment of heart failure in African Americans--a call to action. [2011]

Heart failure in the ethnic minorities. [2010.03]

Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. [2009.12]

Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. [2009.04]

Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2007.11]

Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. [2005.09]

Endothelial dysfunction and nitric oxide enhancing therapy: a new approach to the treatment of heart failure. [2004.09]

The African-American Heart Failure Trial: background, rationale and significance. [2002.09]

Endogenous endothelin-1 limits exercise-induced vasodilation in hypertensive humans. [2002.08]

African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. [2002.06]

L-arginine augments cardiac vagal control in healthy human subjects. [2002.01]

[Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns] [2001.09]

Left ventricle and arteries: structure, function, hormones, and disease. [2001.02]

The generalizability of trial data; a comparison of beta-blocker trial participants with a prospective cohort of women taking beta-blockers in pregnancy. [2001.02]

The effect of patient positioning on intraabdominal pressure and blood loss in spinal surgery. [2000.09]

Nitric oxide and cardiac autonomic control in humans. [2000.08]

Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans. [2000.01.18]

Donor treatment with phentolamine mesylate improves machine preservation dynamics and early renal allograft function. [2000.01.15]

Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. [1999.09]

Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. [1997.04.01]

Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT) [1996.03.01]

Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice. [1996.02]

Oral nifedipine therapy in the management of severe preeclampsia. [1995.06]

Plasma norepinephrine and mortality. [1995.03]

Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. [1995.02]

Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. [1995]

Differential effects of ACE inhibitors and vasodilators on renal function curve in patients with primary hypertension. [1993.12]

Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]

Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group. [1993.06]

Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]

Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group. [1993.06]

Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. [1993.06]

Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group. [1993.06]

Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group. [1993.06]

Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]

Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group. [1993.06]

The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. [1993.06]

Effect of vasodilator therapy on mortality in chronic congestive heart failure. [1993.05]

The effects of tertatolol on lipid profile. [1993]

Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension. [1992.11]

Non-invasive determination of arterial diameter and distensibility by echo-tracking techniques in hypertension. [1992.07]

Effects of long-term vasodilator therapy on electrocardiographic abnormalities in chronic aortic regurgitation. [1991.10.01]

Early blood pressure control improves pregnancy outcome in primigravid women with mild hypertension. [1991.03.18]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017